Karyopharm Therapeutics Inc (KPTI) - Total Assets
Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) holds total assets worth $96.23 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Karyopharm Therapeutics Inc (KPTI) shareholders funds for net asset value and shareholders' equity analysis.
Karyopharm Therapeutics Inc - Total Assets Trend (2011–2025)
This chart illustrates how Karyopharm Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Karyopharm Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Karyopharm Therapeutics Inc's total assets of $96.23 Million consist of 95.1% current assets and 4.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 55.8% |
| Accounts Receivable | $26.18 Million | 24.2% |
| Inventory | $4.04 Million | 3.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Karyopharm Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Karyopharm Therapeutics Inc (KPTI) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Karyopharm Therapeutics Inc's current assets represent 95.1% of total assets in 2025, an increase from 95.0% in 2011.
- Cash Position: Cash and equivalents constituted 55.8% of total assets in 2025, down from 90.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 24.2% of total assets.
Karyopharm Therapeutics Inc Competitors by Total Assets
Key competitors of Karyopharm Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Karyopharm Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.03 | 3.00 | 974.88 |
| Quick Ratio | 0.98 | 2.93 | 965.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.59 Million | $123.26 Million | $289.24 Million |
Karyopharm Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Karyopharm Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.05 |
| Latest Market Cap to Assets Ratio | 1.45 |
| Asset Growth Rate (YoY) | -34.1% |
| Total Assets | $108.42 Million |
| Market Capitalization | $157.11 Million USD |
Valuation Analysis
Above Book Valuation: The market values Karyopharm Therapeutics Inc's assets above their book value (1.45x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Karyopharm Therapeutics Inc's assets decreased by 34.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Karyopharm Therapeutics Inc (2011–2025)
The table below shows the annual total assets of Karyopharm Therapeutics Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $108.42 Million | -34.06% |
| 2024-12-31 | $164.42 Million | -31.62% |
| 2023-12-31 | $240.44 Million | -32.87% |
| 2022-12-31 | $358.17 Million | +17.32% |
| 2021-12-31 | $305.31 Million | -2.47% |
| 2020-12-31 | $313.05 Million | +6.13% |
| 2019-12-31 | $294.96 Million | -13.55% |
| 2018-12-31 | $341.19 Million | +89.24% |
| 2017-12-31 | $180.29 Million | -0.05% |
| 2016-12-31 | $180.38 Million | -16.27% |
| 2015-12-31 | $215.44 Million | -2.22% |
| 2014-12-31 | $220.34 Million | +39.25% |
| 2013-12-31 | $158.23 Million | +11969.11% |
| 2012-12-31 | $1.31 Million | -81.85% |
| 2011-12-31 | $7.22 Million | -- |
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more